VRTX is pressing against trendline resistance after clean higher lows. A breakout above $469.80 could fuel a move toward $471.50.
🎯 Plan:
→ Entry: $468.41
→ SL: Below $466
→ Target: $471.50
⚠️ Wait for confirmation above structure.
VX1 trade ideas
VRTX Tight Triangle Breakout – Watch Closely
🧠 Chart Analysis Summary:
Pattern: A symmetrical triangle is visible, tightening toward the apex with a breakout just forming.
Current Price: $472.47 (breakout near)
Key Levels:
Support Zone: Around $468–470 (white/yellow zone)
Resistance Zone:
First Target: $477.01 (red line)
Major Target: $482.20 (green line)
Volume Confirmation: Suggested to confirm breakout with volume increase.
📊 Trade Idea (Long Setup):
Entry: $472.50–473.00
Target 1: $477.00
Target 2: $482.00
Stop-Loss: Below $468.00
Not many areas confident of a continuationConsolidating, for sure. However, it doesn't seem to have the drive and momentum for continuation unless more buyers come in; this is pointing in a very bearish direction.
Replenishment mid 400s? Surely?As it happens, this is from earlier, but now that we're seeing the same signs we did previously, it suggests the same can happen.
Its either now or never as it reaches previous high testBreak the candle and move on to the 52-week test. This has been turbulent up and down, and there is no escaping the current path to its momentum unless we see a break in structure.
another flush from a promising start 450 not farThe stock swings have been trying to position themselves into an upswing trending faction. However, they have failed to materialize and have LS from making new highs, an early indication that things may need re-evaluation.
VERTEX ($VRTX) SHINES IN Q4—PAIN & CF FUEL GROWTHVERTEX ( NASDAQ:VRTX ) SHINES IN Q4—PAIN & CF FUEL GROWTH
(1/9)
Good evening, Tradingview! Vertex ( NASDAQ:VRTX ) is buzzing—Q4 revenue up 16%, new drugs hit the scene 📈🔥. $ 2.91B and a bold 2025 forecast—let’s unpack this biotech beast! 🚀
(2/9) – REVENUE RUSH
• Q4 Haul: $ 2.91B—16% jump from last year 💥
• Full ‘24: $ 11.02B, up 12%—Trikafta’s king 📊
• ‘25 Outlook: $11.75-$ 12B—6-9% growth
NYSE:CF keeps humming—newbies add zest!
(3/9) – BIG WINS
• Journavx: Non-opioid painkiller greenlit Jan ‘25 🌍
• Alyftrek: CF drug for 6+—ships now 🚗
• Cash: $11.2B—loaded for action 🌟
NASDAQ:VRTX storms pain—CF stays golden!
(4/9) – SECTOR CHECK
• Valuation: 11x sales—above 9x avg 📈
• Vs. Peers: Gilead’s 4x, Regeneron’s 8x—premium?
• Growth: 12% beats biotech’s 5-7% 🌍
NASDAQ:VRTX flexes—value or stretch?
(5/9) – RISKS ON TAP
• Payers: Journavx needs coverage—hiccups? ⚠️
• Trikafta: 93% of sales—big lean 🏛️
• Comp: Pain rivals, CF safe—for now 📉
Hot streak—can it dodge the bumps?
(6/9) – SWOT: STRENGTHS
• CF King: Trikafta, Alyftrek lock it in 🌟
• Pain Play: Journavx eyes $ 4B peak 🔍
• Cash: $11.2B—war chest ready 🚦
NASDAQ:VRTX ’s got muscle and moolah!
(7/9) – SWOT: WEAKNESSES & OPPORTUNITIES
• Weaknesses: Trikafta reliance—eggs in one basket 💸
• Opportunities: Casgevy rolls, pain grows 🌍
Can NASDAQ:VRTX zap past the risks?
(8/9) – NASDAQ:VRTX ’s Q4 surge—what’s your vibe?
1️⃣ Bullish—Pain pays off big.
2️⃣ Neutral—Solid, but risks linger.
3️⃣ Bearish—Growth hits a wall.
Vote below! 🗳️👇
(9/9) – FINAL TAKEAWAY
NASDAQ:VRTX ’s $2.91B Q4 and Journavx/Alyftrek wins spark buzz—$11.2B cash backs it 🌍🪙. Trikafta rules, risks hover—champ or chaser?
$VRTX with a bullish outlook following its earnings #StocksThe PEAD projected a bullish outlook for NASDAQ:VRTX after a negative under reaction following its earnings release placing the stock in drift D with an expected accuracy of 85.71%.
Vertex Pharmaceuticals Pulls Back After RallyVertex Pharmaceuticals ended January with a big rally. Now, after a pullback, some traders may see an opportunity.
The first pattern on today’s chart is the price gap on January 31 after the FDA approved its Journavx painkiller. (It’s the first of its kind to treat pain in a unique way without addiction risks.) The stock has retraced the surge, which may appeal to dip buyers.
Second is the October 7 close of $448.60. VRTX held that level in late November and again on December 18 before gapping down. The stock is now trying to stabilize in the same location, suggesting support may remain in effect.
Next, the MACD surge in January could reflect bullish short-term momentum. Prices are also trying to hold the rising 21-day exponential moving average.
Finally, VRTX is near its 50-, 100- and 200-day simple moving averages. That may create potential for the longer-term trend to accelerate if the short-term strength continues.
TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. If you're born to trade, we could be for you. See our Overview for more.
Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options or futures); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors.
Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission and a futures commission merchant licensed with the Commodity Futures Trading Commission). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association, and a number of exchanges.
TradeStation Securities, Inc. and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., both operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.
Can Pain Be Managed Without Addiction?Vertex Pharmaceuticals has achieved a monumental breakthrough in pain management, securing FDA approval for Journavx, the first new class of painkiller in over 20 years. This non-opioid drug introduces a paradigm shift, targeting pain signals directly at the source without the addictive risks associated with traditional analgesics. The significance of this development cannot be overstated, as it promises a new era where acute pain can be treated effectively and safely, potentially altering the landscape of medical treatment for millions.
Journavx operates by selectively inhibiting NaV1.8, a sodium channel vital for pain signaling, thus preventing pain signals from reaching the brain. This mechanism not only offers relief but does so without the side effects that have long plagued opioid use. The implications for healthcare are profound, offering doctors and patients alike a tool that can redefine how we approach pain management in clinical settings. Vertex's success with Journavx showcases the company's commitment to pioneering treatments that address some of the most pressing needs in modern medicine.
Financially, this approval has bolstered Vertex's market position, evidenced by a significant uptick in stock performance following the announcement. With a revenue projection for 2025 set between $11.75 and $12.0 billion, Vertex is not just riding the wave of this single approval but is also expanding its therapeutic horizons. The strategic leadership transitions announced alongside this approval signal a robust plan for future innovation, challenging investors and healthcare professionals to think about the evolving landscape of drug development and patient care.
This moment invites us to ponder the future of pharmaceuticals - one where efficacy does not compromise safety, where innovation in treatment could lead to broader societal benefits by reducing dependency on addictive substances. Vertex's journey with Journavx might just be the beginning of a new chapter in medical science, urging us to envision a world where pain management is humane and humane-centered.
Reversal on Vertex Pharmaceuticals. VRTXMean reversion strategy in a fade for the most recent rally. Here, we are betting that the rally, now in OBOS, will not cross the most recent high of highs. More specifically, that the price action will not exceed one std deviation of the vWAP value. There are divergences on the indicators below to support trend weakness, and historically nothing stays in OBOS too long. Ellioticians may appreciate a flat forming now.
$VRTX, Long, TP>25% NASDAQ:VRTX , Long, TP>25%
Fundamentally the stock is good.
Choose an entry point and do not forget about a protective order if you are trading with leverage.
Don't risk it if you're not sure.
Good luck to everyone.
VRTX"A quick trade for traders based on a classic, well-known pattern: Symmetrical Triangle. Entry at $500, stop loss at $460. First target between $527.5 _ $535. Second target between $544 _ $549."
VRTXThe VRTX stock has broken the ascending channel and successfully retested it. It is now ready to be sold with a first target between $404.60 and $403, and a second target of $375.50. The stop loss is at $500.
VRTX Vertex Pharmaceuticals Options Ahead of EarningsAnalyzing the options chain and the chart patterns of VRTX Vertex Pharmaceuticals prior to the earnings report this week,
I would consider purchasing the 472.5usd strike price Puts with
an expiration date of 2024-11-8,
for a premium of approximately $14.00.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Vertex Pharmaceuticals (VRTX) | Chart & Forecast SummaryRight Here You Can See Vertex Pharmaceuticals Incorporated (VRTX) Registered As (VRTX) On The New York Stock Exchange, Vertex Pharmaceuticals Incorporated Is An American Biopharmaceutical Company Based In Boston, Massachusetts.
The Following Chart & Forecast Summary On Vertex Pharmaceuticals Incorporated (VRTX) Has been Subject On
Key Indicators on A Trade Set Up in General Like A
1. A Push Set Up
2. A Range Set up
3. And A Break & Retest Set Up
Overall Conclusion | Like The Trade Plan Execution & Risk Management on Demand It Tells Us
"Long Bias For Now"
VRTX Bull FlagVRTX is approaching the top end of bull flag on the 4hr. A break could lead to a move back up to ATH and beyond. The flag pole on this one is pretty big so if going on that projection it could see $600 if it does get continuation above.
A bearish scenario would be a rejection here at the top end or a fakeout above that could lead to a move all the way back down to the bottom end of the flag. Looking bullish for now.
Buy Vertex PharmaceuticalsShort Term Trading Advice by Naranj Capital
Buy Vertex Pharmaceuticals
● Buy Range- 475 - 480
● Target- 500 - 505
● StopLoss- 460
● Potential Return- 5-6%
● Duration- 12-14 Trading Days
VRTX upside?Beautiful bullflag breaking on the hourly and higher time frames, Targeting previous highs
Eyes on VRTXVRTX bouncing nicely off recent lows and has broken downtrend. Final confirmation would be a daily close over 421.50. Looking to enter a starter position and will add on a retest of the daily 48.
Vertex Pharmaceuticals pioneers with non-opioid painkiller VX-54Vertex Pharmaceuticals Inc., widely recognised for its cystic fibrosis treatments, is venturing into new therapeutic areas , signalling potential growth in new markets. The company is currently advancing its development of non-opioid analgesics, specifically candidate VX-548, which has demonstrated encouraging outcomes in clinical trials. This new drug represents a significant shift in pain management, offering an alternative to opioid medications.
Vertex is preparing to seek FDA approval for VX-548 within the year. If approved, this drug could substantially impact the healthcare industry and is projected to achieve peak annual revenues of 5 billion USD – approximately half of Vertex's current annual revenue.
Exploring investment opportunities, here is a technical analysis of Vertex Pharmaceuticals Inc. (NASDAQ: VRTX):
On the Daily (D1) timeframe, the stock exhibits a 410.00 USD resistance level and support at 392.00 USD. The stock is currently trending downward. Notably, there have been three consecutive trading sessions with a gap up, suggesting that major players might be accumulating buy positions. If the downtrend persists, the next price target could be around 360.50 USD.
For traders, breaking the resistance at 410.00 USD could provide a buying opportunity, with a short-term target set at 421.00 USD. If the resistance is surpassed, holding a long position with a target of up to 436.50 USD might be considered for a medium-term strategy.
—
Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews.
The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments.
Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69.88% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
In waiting for a retestAre you interrested in buying NASDAQ:VRTX ? I'm looking for a break confirmation of the 2-years trendline to evaluate a first entry in the 370s. Then the POC line could be a valid support to regain the trend.
